Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by brad129on Dec 03, 2020 12:37am
106 Views
Post# 32024152

RE:BASHERS NEVER BASH A BAD STOCK

RE:BASHERS NEVER BASH A BAD STOCK

didn't I just read $749 for the viral panel test, what would cancer panel test be worth, have you checked out the slides for sensitivity and specificity for Aristotle? Grail valued at 8billion explain that please, just so we know how they got that valuation, have you even seen their published numbers? We did have much higher SP with really nothing concrete no revenue, so now with 4 times the revenue in one quarter than all of last year we should have a lower Valuation? Explain that logic would you?



VerifiedUser123 wrote: Nope only speak the truth. You guys are hilarious. Talking out of both sides of your mouth. 3000 tests a day we'll be doing this, multi dollar valuation that. Now I'm seeing range bound until Arist-dam-otle. My god this better pan out for all of our sakes.

 

<< Previous
Bullboard Posts
Next >>